Repligen Co. (NASDAQ:RGEN) Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. trimmed its position in shares of Repligen Co. (NASDAQ:RGEN) by 4.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,783 shares of the biotechnology company’s stock after selling 505 shares during the period. Pacer Advisors Inc.’s holdings in Repligen were worth $1,696,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in RGEN. The Manufacturers Life Insurance Company grew its holdings in Repligen by 4.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 67,701 shares of the biotechnology company’s stock valued at $8,534,000 after purchasing an additional 2,946 shares in the last quarter. SG Americas Securities LLC grew its holdings in Repligen by 131.3% during the 3rd quarter. SG Americas Securities LLC now owns 6,520 shares of the biotechnology company’s stock worth $970,000 after acquiring an additional 3,701 shares in the last quarter. GAMMA Investing LLC grew its holdings in Repligen by 24.0% during the 3rd quarter. GAMMA Investing LLC now owns 594 shares of the biotechnology company’s stock worth $88,000 after acquiring an additional 115 shares in the last quarter. Diversified Trust Co grew its holdings in Repligen by 255.0% during the 3rd quarter. Diversified Trust Co now owns 10,469 shares of the biotechnology company’s stock worth $1,558,000 after acquiring an additional 7,520 shares in the last quarter. Finally, Artemis Investment Management LLP grew its holdings in Repligen by 48.0% during the 3rd quarter. Artemis Investment Management LLP now owns 129,927 shares of the biotechnology company’s stock worth $19,336,000 after acquiring an additional 42,118 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

RGEN has been the subject of several recent analyst reports. Wolfe Research initiated coverage on shares of Repligen in a report on Thursday, November 14th. They set a “peer perform” rating for the company. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. HC Wainwright decreased their price objective on shares of Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Canaccord Genuity Group assumed coverage on shares of Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. Finally, Canaccord Genuity Group assumed coverage on shares of Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and an average target price of $184.73.

Repligen Trading Down 0.8 %

Shares of NASDAQ:RGEN opened at $166.21 on Friday. The company has a market cap of $9.31 billion, a PE ratio of -449.20, a P/E/G ratio of 4.76 and a beta of 0.97. The company’s 50-day moving average price is $154.24 and its 200 day moving average price is $147.73. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. The firm had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. Repligen’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period last year, the firm posted $0.23 EPS. Sell-side analysts anticipate that Repligen Co. will post 1.54 earnings per share for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.